Clinical trial
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
NCT00030056 · The Cleveland Clinic, Other · Terminated
Key facts
| NCT number | NCT00030056 |
|---|---|
| Title | GM-CSF in Patients With Pulmonary Alveolar Proteinosis |
| Official title | Trial of GM-CSF for Alveolar Proteinosis |
| Lead sponsor | The Cleveland Clinic, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Alveolar Proteinosis |
| Intervention type | Drug |
| Interventions | GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) |
| Enrollment | 48 |
| Start date | Sep 1, 2001 |
| Completion | Dec 1, 2005 |
| First posted | Jan 31, 2002 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: